Drugs / GMA106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05054530 | Nov 2021 → Nov 2023 | — | Gmax Biopharm Australia Pty Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GMA106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05054530 ↗ |
| Route | Subcutaneous | “GMA106 SC injection” NCT05054530 ↗ |